Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 115 for “"MEK1/2"”.

  1. U0126, MEK1/2 inhibitor, Induces Adhesion Molecules Expression in Human Blood Cells

    … the expression of adhesion molecule by MEK1/2 inhibotors such as U0126 in human blood cells, U937 cells. Cell viability was determined by MTT assay. The expression of adhesion molecule was observed by flow cytometry. Adhesion molecules were time- and dose-dependently incresed by U0126. …

    ajou Repository record for U0126, MEK1/2 inhibitor, Induces Adhesion Molecules Expression in Human Blood Cells (opens in a new tab) Embargoed until 9999-12-31

  2. Ex vivo model of human colorectal tumours to study response to the MEK1/2 inhibitor AZD6244

    … increased proliferation and tumour survival. The MEK1/2 inhibitor AZD6244, that targets the MAPK pathway downstream of these mutations, has been tested as novel therapy for colorectal cancer. However, clinical trials have been disappointing due to an apparent intrinsic and/or acquired resistance …

    edinburgh Repository record for Ex vivo model of human colorectal tumours to study response to the MEK1/2 inhibitor AZD6244 (opens in a new tab)

  3. Leveraging the Requirement of MEK1/2 Kinases for Copper to Inhibit the MAPK Pathway in Oncogenic BRAF-Driven Cancer

    … BRAFV600E phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate the ERK1 and ERK2 kinases of the MAPK pathway to promote tumorigenesis. Targeting this pathway is a well-validated strategy to treat BRAF-mutant cancer. Inhibitors of both BRAFV600E and the MEK1/2 …

    duke Repository record for Leveraging the Requirement of MEK1/2 Kinases for Copper to Inhibit the MAPK Pathway in Oncogenic BRAF-Driven Cancer (opens in a new tab)

  4. BLOCKADE OF CXCR2 OVERCOMES NEUTROPHIL-MEDIATED RESISTANCE TO COMBINED ANTI-PD-1 AND MEK1/2 INHIBITON IN MURINE PANCREATIC DUCTAL ADENOCARCINOMA

    … inhibition of the downstream KRAS effector MEK1/2 in combination with aPD-1 blockade. aPD-1+MEKi therapy routinely eradicated tumors in >80% of mice, with tumor-free survival and protection from tumor re-challenge extending as far as one-year post-treatment. Initial gene expression data …

    jhu Repository record for BLOCKADE OF CXCR2 OVERCOMES NEUTROPHIL-MEDIATED RESISTANCE TO COMBINED ANTI-PD-1 AND MEK1/2 INHIBITON IN MURINE PANCREATIC DUCTAL ADENOCARCINOMA (opens in a new tab)

  5. The role of MEK1/2 and MEK5 in melatonin-mediated actions on osteoblasts and osteoclasts differentiation, bone formation, bone microarchitecture, and bone biomechanics

    … indicating the potential role of the MAPKs, MEK1/2/ERK1/2 and MEK5/ERK5 pathways in mediating melatonin’s action. To investigate this further, the goal of this project was to study the role of MEK1/2 and MEK5 in regulating melatonin-mediated osteoblast and osteoclast differentiation and …

    duquesne Repository record for The role of MEK1/2 and MEK5 in melatonin-mediated actions on osteoblasts and osteoclasts differentiation, bone formation, bone microarchitecture, and bone biomechanics (opens in a new tab)

  6. THE SMALL MOLECULE BCL-2 INHIBITOR HA14-1 POTENTIATES THE LETHALITY OF A REGIMEN COMBINING MEK1/2 AND CHK1 INHIBITORS IN MULTIPLE MYELOMA CELLS

    … we have found that the co-administration of MEK1/2 inhibitors and Chk1 inhibitors synergistically induce multiple myeloma cell apoptosis through upregulation of the BH3-only pro-apoptotic protein Bim. However, these apoptotic events were largely blocked by the characteristic over-expression …

    vcu Repository record for THE SMALL MOLECULE BCL-2 INHIBITOR HA14-1 POTENTIATES THE LETHALITY OF A REGIMEN COMBINING MEK1/2 AND CHK1 INHIBITORS IN MULTIPLE MYELOMA CELLS (opens in a new tab)

  7. Targeting the MEK5, MEK1/2, and/or PI3K Pathways to Reverse Epithelial to Mesenchymal Transition and Enhance Chemotherapeutic Sensitivity in Breast And Brain Cancers

    Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and accounts for 10-15% of breast cancer cases. Due to absence of estrogen, progesterone, and human epidermal growth factor receptors, there is lack of targeted therapies and chemotherapy remains the mainstay …

    duquesne Repository record for Targeting the MEK5, MEK1/2, and/or PI3K Pathways to Reverse Epithelial to Mesenchymal Transition and Enhance Chemotherapeutic Sensitivity in Breast And Brain Cancers (opens in a new tab)

  8. Regulation von MAPK Signalwegen durch die Sein/Threonin Kinase MLK3

    … phosphoryliert MLK3 die dualspezifischen Kinasen MEK1/2 direkt in vitro und in vivo an den für die Aktivierung wichtigen Serinen 217/221. Wohingegen dies nur zu einer ERK Aktivierung in Überexpressionssystemen führte, demonstrieren die Analysen überzeugend, dass endogenes MEK1/2, welches von MLK3 …

    wurz-thes Repository record for Regulation von MAPK Signalwegen durch die Sein/Threonin Kinase MLK3 (opens in a new tab)

  9. Therapeutic Targeting Of Bmp2 In Nf1-Deficient Malignant Peripheral Nerve Sheath Tumors (mpnsts)

    … target in MPNSTs, independent of the NRAS and MEK1/2 regulation. The overall goal of my research was to validate the significance of BMP2 in MPNSTs in novel cellular models, study the combinatorial effects of BMP2 and MEK1/2 inhibition, and use the regulation of BMP2 transcriptional control to …

    wayne-thes Repository record for Therapeutic Targeting Of Bmp2 In Nf1-Deficient Malignant Peripheral Nerve Sheath Tumors (mpnsts) (opens in a new tab)

  10. Leveraging copper chelators as targeted therapy for BRAFV600E mutant thyroid cancer

    … this mutant kinase or its substrates, the MEK1/2 kinases, can prolong progression free survival or stabilize disease in radioiodine-refractory thyroid cancer patients. However, the indolent nature of PTC may be a challenge to the clinical adaption of these inhibitors, as the financial and …

    duke Repository record for Leveraging copper chelators as targeted therapy for BRAFV600E mutant thyroid cancer (opens in a new tab)

  11. Role of hypoxia and hypoxia induced factors in the development of breast cancer brain metastasis

    … VEGFR2 by using specific PI3K inhibitor. Using MEK1/2 inhibitor we showed that hypoxic regulation of MMP-9, VEGF-A and VEGFR2 also involve MEK1/2-ERK pathway. We also investigated the effect of fibroblast growth factor-1 (FGF-1), one of the factors known to be upregulated by hypoxia, on the …

    tamu Repository record for Role of hypoxia and hypoxia induced factors in the development of breast cancer brain metastasis (opens in a new tab)

  12. THE ONCOGENIC ROLE OF TREFOIL FACTOR 3 (TFF3) IN NON-SMALL CELL LUNG CANCER (NSCLC)

    … upregulating ARAF and activating downstream MEK1/2 and ERK1/2. Importantly, pharmacological inhibition of TFF3 by AMPC, a small molecular TFF3 inhibitor, resulted in markedly decreased cell survival, proliferation, 3D growth, foci formation and drastically stalled tumor growth in xenograft …

    nus Repository record for THE ONCOGENIC ROLE OF TREFOIL FACTOR 3 (TFF3) IN NON-SMALL CELL LUNG CANCER (NSCLC) (opens in a new tab) Download file for THE ONCOGENIC ROLE OF TREFOIL FACTOR 3 (TFF3) IN NON-SMALL CELL LUNG CANCER (NSCLC) (opens in a new tab)

  13. Exploiting Acquired Resistance Mechanisms To Mek Inhibition In Ras-Activated Neuroblastoma

    … upon relapse that are potentially sensitive to MEK1/2 inhibition with drugs such as trametinib. Although trametinib is a potent MEK1/2 inhibitor, single-agent therapy invariably encounters de novo or acquired bypass mechanisms that allow for disease progression. The central goal of this …

    penn Repository record for Exploiting Acquired Resistance Mechanisms To Mek Inhibition In Ras-Activated Neuroblastoma (opens in a new tab)

  14. Evaluation of inhibitors of histone deacetylases as potential neurotrophic agents

    … were interrogated with selective inhibitors of MEK1/2 (PD98059/U0126) PI3K (LY294002) and TrkA (GW441756) and phosphorylation of target kinases. Associated factors namely, acetylation of histones (H3/H4) and α-tubulin, role of cAMP, and cell- cycle analysis with flowcytometry were also studied. …

    mississippi Repository record for Evaluation of inhibitors of histone deacetylases as potential neurotrophic agents (opens in a new tab)

  15. Negative regulation of oncogenic Ras signaling by mitogen-activated protein kinase phosphatase-3.

    … signaling pathways, such as the Raf/MEK1/2/ERK1/2 protein kinase cascade, that modulate cell cycle progression, cell proliferation, and cell survival. Chronic activation of Ras-stimulated pathways is believed to play a key role in cellular transformation, although constitutive …

    umn Repository record for Negative regulation of oncogenic Ras signaling by mitogen-activated protein kinase phosphatase-3. (opens in a new tab)

  16. Elevated Phosphate-Induced Cell Signaling through Phosphate Transporter PiT-1 in Vascular Smooth Muscle Cells

    … ERK1/2 phosphorylation through a Rap1/B-Raf/Mek1/2 pathway that promotes VSMC phenotype change. Together, the data presented here shows that elevated Pi promotes PiT-1 binding to RapGEF1 and ERK1/2 phosphorylation through Rap1/B-Raf/Mek1/2, which induces osteochondrogenic differentiation and …

    washington Repository record for Elevated Phosphate-Induced Cell Signaling through Phosphate Transporter PiT-1 in Vascular Smooth Muscle Cells (opens in a new tab)

  17. A SINGLE AMINO ACID SUBSITUTION HUMANIZES MOUSE CD28, INCREASING EFFECTOR AND STEM-LIKE T CELL ACTIVATION

    … JunB, IL-2, and inhibitory receptors driven by MEK1/2. Depletion of CD8 T cells or inhibition of MEK1/2 prevented the pro-inflammatory response to CD28 superagonist antibody in CD28A210P mice without inhibiting Foxp3+ regulatory T cell expansion. Thus, ‘humanized’ PYAP mice reveal key roles for …

    cornell Repository record for A SINGLE AMINO ACID SUBSITUTION HUMANIZES MOUSE CD28, INCREASING EFFECTOR AND STEM-LIKE T CELL ACTIVATION (opens in a new tab)

  18. Mechanisms of Proteinase-Activated Receptor 2-Induced Inhibition of Intestinal Epithelial Apoptosis

    … apoptosis. Concurrent inhibition of MEK1/2 and PI3K was necessary to inhibit PAR2-induced survival. PAR2 activation was found to increase phosphorylation and inactivation of pro-apoptotic BCL-2 antagonist of cell death (BAD) at Ser112 and Ser136 by MEK1/2 and PI3K-dependent signaling, …

    calgary Repository record for Mechanisms of Proteinase-Activated Receptor 2-Induced Inhibition of Intestinal Epithelial Apoptosis (opens in a new tab)

  19. ERK1/2 Activation in Macrophages Is Necessary for Efficient Leishmania amazonensis Internalization and Pathogenesis

    … Consistent with these results, we hypothesized MEK1/2 or ERK1/2 inhibition in macrophages leads to production of large F-actin-rich phagocytic cups, showcasing a defective phagocytic process. Interestingly, ERK1/2's role in uptake is relatively specific to Leishmania, as beads mildly activate …

    utswmed Repository record for ERK1/2 Activation in Macrophages Is Necessary for Efficient Leishmania amazonensis Internalization and Pathogenesis (opens in a new tab)

  20. Regulation and functional consequences of MCP-1 expression in a model of Charcot-Marie-Tooth 1B disease

    … /MCP 1+/+ mice. Furthermore, activation of the MEK1/2-ERK1/2 signalling cascade could be demonstrated to take place in Schwann cells of affected peripheral nerves of P0+/- mice overlapping temporarily and spatially with MCP-1 expression. An animal experiment using a MEK1/2-inhibitor in vivo, …

    wurz-thes Repository record for Regulation and functional consequences of MCP-1 expression in a model of Charcot-Marie-Tooth 1B disease (opens in a new tab)

Page 1 of 6